Dr María Natalia Gandur Quiroga speaks to ecancer about the major breakthroughs in urothelial (bladder) carcinoma.

She says the recent data signals a true turning point in the field, moving beyond incremental progress toward a complete transformation of treatment strategies.

In this expert update, she explores how perioperative care is being redefined, antibody drug conjugates (ADCs) are expanding rapidly, and molecular biomarkers are beginning to guide real clinical decisions.